Pharma major Novartis falls nearly 10%, heading for worst day on record after three drug trial setbacks
Shares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company statnews.com
- Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drug endpoints.news
- Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff marketwatch.com
